- Pyrazole derivative for FGFR inhibitor and preparation method of pyrazole derivative
-
The invention provides a pyrazole derivative for an FGFR inhibitor and a preparation method of the pyrazole derivative. The invention specifically relates to an amide pyrazole compound serving as an FGFR irreversible inhibitor, and a preparation method and application thereof. The present invention provides a compound as shown in Formula I, or a pharmaceutically acceptable salt, or solvate, isotope substitute, prodrug, or metabolite thereof. The compound as shown in general formula I have FGFR inhibitory activity, and is capable of preventing or treating disorders associated with FGFR activityor expression, preferably such as cancer.
- -
-
Paragraph 0258-0262
(2021/03/06)
-
- Preparation method of 1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)propyl-1,3-dione
-
The invention provides a preparation method of 1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)propyl-1,3-dione, and belongs to the technical field of organic synthesis. The preparation method comprises following steps: (1) mixing 2-nitro-4-trifluor
- -
-
Paragraph 0062-0066; 0068-0072
(2019/07/04)
-
- Preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate
-
The invention discloses a preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate, belongs to the technical field of organic synthesis, and solves the technical problem that a new method forpreparing the methyl 2-nitryl-4-trifluoromethyl benzoate is provided. The method comprises the following steps: performing alkali catalytic or acid catalytic hydrolysis on 2-nitryl-4-trifluoromethyl benzonitrile to prepare 2-nitryl-4-trifluoromethyl phenyl methyl amide; mixing the 2-nitryl-4-trifluoromethyl phenyl methyl amide with a sulfuric acid-methanol solution and performing alcoholysis reaction to obtain the methyl 2-nitryl-4-trifluoromethyl benzoate. The method disclosed by the invention has the advantages of mild reaction conditions and simple post-processing; moreover, the high-puritymethyl 2-nitryl-4-trifluoromethyl benzoate can be obtained in a form of high yield, and realization of industrial production is facilitated.
- -
-
Paragraph 0079; 0081-0082
(2018/07/30)
-
- Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
Page/Page column 10
(2008/12/04)
-
- Novel Heterocyclidene Acetamide Derivative
-
A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,
- -
-
Page/Page column 65
(2008/12/09)
-
- NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE
-
A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,
- -
-
Page/Page column 99
(2010/11/30)
-
- FUSED HETEROCYCLIC COMPOUNDS
-
There is provided a CRF receptor antagonist comprising a compound of the formula (I) : wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano
- -
-
Page/Page column 223; 224
(2008/06/13)
-
- COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
-
Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
- -
-
Page/Page column 55
(2010/02/15)
-
- Quinoxaline compounds
-
Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
- -
-
Page/Page column 27
(2008/06/13)
-
- INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
-
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
Page/Page column 21
(2010/02/11)
-
- Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
-
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-
- Benzo[1,2,5]thiadiazole compounds
-
Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
- -
-
-
- Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
-
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- -
-
-
- Preparation of C1-C5 alkyl esters of nitro or thioether substituted aromatic carboxylic acids
-
Methods for preparing substituted aromatic carboxylic acid esters are described. In particular, the invention relates a method for preparing a nitro-substituted aromatic carboxylic acid ester: Additionally the invention relates to a method for preparing a
- -
-
-